MX2018002707A - Derivados de tetrahidrofurano antivirales. - Google Patents

Derivados de tetrahidrofurano antivirales.

Info

Publication number
MX2018002707A
MX2018002707A MX2018002707A MX2018002707A MX2018002707A MX 2018002707 A MX2018002707 A MX 2018002707A MX 2018002707 A MX2018002707 A MX 2018002707A MX 2018002707 A MX2018002707 A MX 2018002707A MX 2018002707 A MX2018002707 A MX 2018002707A
Authority
MX
Mexico
Prior art keywords
compounds
viral
tetrahydrofurane
derivatives
tetrahydrofurane derivatives
Prior art date
Application number
MX2018002707A
Other languages
English (en)
Spanish (es)
Inventor
A Degoey David
C Krueger Allan
T Randolph John
Wagner Rolf
R Heyman Howard
Voight Eric
CHAU Jaclyn
Ju J Chen Hui-
Hartung John
Ide Nathan
Kalthod Vikram
Yin KU Yi-
Li Tongmei
T Halvorsen Geoff
C Marvin Christopher
S Brown Brian
R Martinez Steven
Shrestha Anurupa
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2018002707A publication Critical patent/MX2018002707A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/6512—Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MX2018002707A 2015-09-02 2016-09-01 Derivados de tetrahidrofurano antivirales. MX2018002707A (es)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562213378P 2015-09-02 2015-09-02
US201562242136P 2015-10-15 2015-10-15
US201562253426P 2015-11-10 2015-11-10
US201662294449P 2016-02-12 2016-02-12
US201662296801P 2016-02-18 2016-02-18
US201662321538P 2016-04-12 2016-04-12
US201662327087P 2016-04-25 2016-04-25
US201662351038P 2016-06-16 2016-06-16
US201662363640P 2016-07-18 2016-07-18
US201662375029P 2016-08-15 2016-08-15
PCT/US2016/049873 WO2017040766A1 (en) 2015-09-02 2016-09-01 Anti-viral tetrahydrofurane derivatives

Publications (1)

Publication Number Publication Date
MX2018002707A true MX2018002707A (es) 2018-08-01

Family

ID=56926317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002707A MX2018002707A (es) 2015-09-02 2016-09-01 Derivados de tetrahidrofurano antivirales.

Country Status (7)

Country Link
US (2) US9676797B2 (OSRAM)
EP (1) EP3344642A1 (OSRAM)
JP (1) JP6743135B2 (OSRAM)
CN (1) CN108350016B (OSRAM)
CA (1) CA2997170A1 (OSRAM)
MX (1) MX2018002707A (OSRAM)
WO (1) WO2017040766A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX382566B (es) * 2015-05-01 2025-03-13 Univ Emory Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer
CN108350016B (zh) * 2015-09-02 2021-07-27 艾伯维公司 抗病毒四氢呋喃衍生物
US20190358214A1 (en) * 2016-11-17 2019-11-28 Abbvie Inc. Compositions and Methods for Treating HCV Infection
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
MX2020007393A (es) 2018-01-10 2020-11-24 Nucorion Pharmaceuticals Inc Compuestos de fósforo(n)amidatacetal y fosf(on)atalcetal.
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CN109762040A (zh) * 2019-01-14 2019-05-17 歌礼生物制药(杭州)有限公司 一种核苷类ns5b聚合酶抑制剂的制备方法
AU2020315394A1 (en) 2019-07-17 2022-02-17 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US5246924A (en) 1987-09-03 1993-09-21 Sloan-Kettering Institute For Cancer Research Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil
SE8802687D0 (sv) 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
US6060592A (en) 1990-01-11 2000-05-09 Isis Pharmaceuticals, Inc. Pyrimidine nucleoside compounds and oligonucleoside compounds containing same
US6060542A (en) 1997-05-16 2000-05-09 Shell Oil Company Bitumen compositions and a process for their preparation
KR100954390B1 (ko) 1998-02-25 2010-04-26 에모리 유니버시티 2'-플루오로뉴클레오사이드
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US6596700B2 (en) 2000-05-26 2003-07-22 Idenix Pharmaceuticals Inc. Methods of treating hepatitis delta virus infection with β-L-2'-deoxy-nucleosides
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
CZ301182B6 (cs) 2000-05-26 2009-12-02 Idenix (Cayman) Limited Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP1330459B1 (en) * 2000-10-02 2006-08-02 Emory University Triptolide analogs for the treatment of autoimmune and inflammatory disorders
DK2251015T3 (da) 2000-10-18 2013-05-13 Gilead Pharmasset Llc Modificerede nukleotider til behandling af virusinfektioner og abnorm celleproliferation
SK286630B6 (sk) 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US7105499B2 (en) 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
WO2003105770A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Carbocyclic nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP2005530843A (ja) 2002-06-21 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害剤としてのヌクレオシド誘導体
US7608600B2 (en) 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
MXPA04012802A (es) 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
WO2004046331A2 (en) 2002-11-15 2004-06-03 Idenix (Cayman) Limited 2’-branched nucleosides and flaviviridae mutation
US7598373B2 (en) 2002-12-12 2009-10-06 Idenix Pharmaceuticals, Inc. Process for the production of 2-C-methyl-D-ribonolactone
KR20060008297A (ko) * 2003-03-20 2006-01-26 마이크로 바이올로지카 퀴미카 이 파마슈티카 리미티드 2'-데옥시-β-Ｌ-뉴클레오시드의 제조방법
EP2345659A1 (en) 2003-05-30 2011-07-20 Pharmasset, Inc. Modified fluorinated nucleoside analogues
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
JP2008523082A (ja) 2004-12-09 2008-07-03 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗菌活性および抗癌活性を有するヌクレオチド
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
AR077060A1 (es) 2009-06-11 2011-07-27 Abbott Lab Compuestos antivirales
WO2011003018A2 (en) 2009-07-01 2011-01-06 Cornell University Halogenated 2-deoxy-lactones, 2'-deoxy--nucleosides, and derivatives thereof
EP2464647B1 (en) * 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
US9700560B2 (en) 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
SMT201700412T1 (it) * 2010-03-31 2017-11-15 Gilead Pharmasset Llc Procedimento per la cristallizzazione di (s)-isopropil 2-(((s)-(perfluorofenossi)(fenossi)fosforil)ammino)propanoato
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
PT3042910T (pt) 2010-11-30 2019-04-16 Gilead Pharmasset Llc 2'-espiro-nucleósidos para utilização na terapia da hepatite c
US9156874B2 (en) * 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections
EA201391519A1 (ru) * 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
US8877733B2 (en) * 2011-04-13 2014-11-04 Gilead Sciences, Inc. 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
EP2794629B1 (en) * 2011-12-20 2017-05-24 Riboscience LLC 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
AU2012357986B2 (en) * 2011-12-20 2017-02-02 Riboscience Llc 4'-Azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
WO2013187978A1 (en) * 2012-06-16 2013-12-19 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
CN102751200B (zh) 2012-06-29 2015-06-10 京东方科技集团股份有限公司 薄膜晶体管、阵列基板及其制造方法
US20140065101A1 (en) * 2012-08-31 2014-03-06 Novartis Ag 2'-Branched Nucleosides for Treatment of Viral Infections
NZ706985A (en) 2012-10-08 2018-08-31 Centre Nat Rech Scient 2’-chloro nucleoside analogs for hcv infection
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
EP2935303B1 (en) 2012-12-21 2021-02-17 Janssen BioPharma, Inc. 4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
CA2909270A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv
HK1224229A1 (zh) 2013-06-26 2017-08-18 Alios Biopharma, Inc. 取代的核苷，核苷酸及其类似物
UA117375C2 (uk) * 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
HRP20220911T1 (hr) 2013-09-11 2022-10-28 Emory University Sastav nukleotida i nukleozida i njihova uporaba
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015056213A1 (en) 2013-10-17 2015-04-23 Medivir Ab Hcv polymerase inhibitors
WO2015077360A2 (en) * 2013-11-20 2015-05-28 Idenix Pharmaceuticals, Inc. Cyclopentane and cyclopentene nucleoside analogs for the treatment of hcv
EP3074399A1 (en) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
EP3102188A4 (en) * 2014-02-05 2017-07-12 Merck Sharp & Dohme Corp. Novel disintegration systems for pharmaceutical dosage forms
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CA2946867C (en) 2014-04-24 2023-03-07 Cocrystal Pharma, Inc. 2'-disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
CA2966033A1 (en) 2014-10-31 2016-05-06 Cocrystal Pharma, Inc. 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
MX382566B (es) * 2015-05-01 2025-03-13 Univ Emory Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer
CN108350016B (zh) * 2015-09-02 2021-07-27 艾伯维公司 抗病毒四氢呋喃衍生物

Also Published As

Publication number Publication date
US20180022763A1 (en) 2018-01-25
WO2017040766A1 (en) 2017-03-09
US20170057981A1 (en) 2017-03-02
JP6743135B2 (ja) 2020-08-19
JP2018529671A (ja) 2018-10-11
CA2997170A1 (en) 2017-03-09
CN108350016B (zh) 2021-07-27
US10053474B2 (en) 2018-08-21
CN108350016A (zh) 2018-07-31
EP3344642A1 (en) 2018-07-11
US9676797B2 (en) 2017-06-13

Similar Documents

Publication Publication Date Title
MX2018002707A (es) Derivados de tetrahidrofurano antivirales.
PH12020550531A1 (en) Novel, highly active pyrazolo-piperidine substituted indole2-carboxamides active against the hepatitis b virus (hbv)
PH12020550525A1 (en) Novel, highly active amino-thiazole substituted indole-2carboxamides active against the hepatitis b virus (hbv)
PH12013500708B1 (en) Anti-viral compounds
PH12016501254A1 (en) Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
JOP20180008A1 (ar) مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
MX2022015257A (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
PH12013502033A1 (en) Pyrimidine derivatives for the treatment of viral infections
PH12019500513A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
MX2015011193A (es) Compuestos antivirales.
PH12018502332A1 (en) Stabilized pre-fusion rsv f proteins
PH12016500320A1 (en) Cyclosporin analogues for preventing or treating hepatitis c
PH12014500385A1 (en) Benzofuran compounds for the treatment of hepatitis c virus infections
HK1251010A1 (zh) 用於治疗乙型肝炎病毒(hbv)感染的试剂及用途
GB2544439A (en) Antiviral composition
WO2017161133A8 (en) N-hydroxyisoquinolinedione inhibitors of hbv replication
PH12017500816A1 (en) Long acting pharmaceutical compositions for hepatitis c
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
MX2015010892A (es) Compuestos antivirales.
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
MX2015011125A (es) Compuestos antivirales.
MY164064A (en) Anti-viral compounds